- Home
- ALIS vs PLRX Comparison
ALIS vs PLRX Comparison
Compare ALIS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALIS | PLRX |
|---|---|---|
| Founded | 2024 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 70.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALIS | PLRX |
|---|---|---|
| Price | $10.17 | $1.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 32.0K | ★ 437.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.09 |
| 52 Week High | $10.25 | $1.95 |
Technical Indicators
Market Signals| Indicator | ALIS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.26 | 43.54 |
| Support Level | $10.05 | $1.12 |
| Resistance Level | N/A | $1.37 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 50.00 | 26.67 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.